Dr. Michael Hardy

The Racing Medication and Testing Consortium's (RMTC) Scientific Advisory Committee (SAC) has developed a withdrawal guidance for two additional substances, Dimethyl Sulfoxide (DMSO) and Pentosan (Zycosan) following an analysis of the Horseracing Integrity and Safety Authority's (HISA) Anti-Doping and Medication Control (ADMC) screening limits and detection times. "The intention is for the RMTC to provide the industry with scientifically derived information to aid attending veterinarians and horsemen in making medication decisions and to avoid preventable errors and promote compliance with HISA's regulations", said Dr. Michael Hardy, Executive Director, "The RMTC...

The Racing Medication & Testing Consortium (RMTC)'s part-time Executive Director, Dr. Michael Hardy, has been promoted to full-time Executive Director of the RMTC, the organization announced on Monday. In his new position, Hardy will be responsible for the management of the RMTC's Laboratory Accreditation and External Quality Assurance Program in conjunction with the new Horseracing Integrity and Welfare Unit and will also administer the RMTC's Scientific Advisory Committee (SAC) process, manage the organization's monitoring of emerging threats to the integrity of racing, and oversee the process of reviewing applications received...

Dr. Michael Hardy has been hired as its next Executive Director of the Racing Medication & Testing Consortium. In his new role, Dr. Hardy will be responsible for the management of the RMTC's Laboratory Accreditation and External Quality Assurance Program in conjunction with the new Horseracing Integrity and Welfare Unit. He will also be charged with the administration of the RMTC's Scientific Advisory Committee process, the monitoring of emerging threats to the integrity of racing and the health and welfare of racehorses, administrative oversight of RMTC-funded research projects, and coordinating...